Biomolecular Structure Analysis to Accelerate Develoment of New Vaccines and Monoclonal Antibodies

Manufacturing of consistently high quality products is the commitment of the pharmaceutical industry. To achieve this, new products must be thoroughly tested and the results meet government-approved product specifications. Improving existing and adopting improved analytical technologies for product testing ensure the production of safe and effective products. This is particularly critical for the manufacturing of biologic products which, relative to small molecular drugs, have a larger size, are more complex in structure and are thus more difficult to characterize.

Determination of stress-induced modifications to vaccine proteins by mass spectrometry

The therapeutic effect of a vaccine depends on its chemical composition, and in particular the integrity of its protein components. Conditions under which a vaccine is manufactured and stored can damage the proteins it contains; however, since proteins are structurally complex and reactive, their degradation during routine handling is unpredictable. In the project described here, three candidate vaccine products will be subjected to models of manufacture and storage in order to induce chemical changes within them in a controlled manner.

Health economics and modeling collaboration between sanofi Pasteur and York: pertussis study

Pertussis, caused by the strict human pathogen B. pertussis or Bordetella parapertussis, is a highly contagious, potentially life-threatening respiratory tract illness when it occurs in unprotected infants. Despite the introduction of acellular pertussis (aP) vaccines and great initial success of the immunization program, pertussis outbreaks were reported in adolescents and adults in Canada since 1993. This trend was demonstrated as shift in pertussis epidemiology from infants and young children.

Evaluation of viral sensitizer technology for improving influenza vaccine in an egg-basedmanufacturing process

Vaccination remains the most effective preventative measure for influenza infection. Seasonal influenza epidemics and the emergence of pandemic strains have increased the global demand for influenza vaccines, putting significant pressure on vaccine manufacturers. However, current vaccine manufacturing strategies rely primarily upon production in eggs, an age-old method that needs to be significantly improved. Recently, research from our lab identified a panel of novel compounds termed viral sensitizers (VSes) that increased virus production up to 1000 fold in cultured cells.

Biomolecular Structure Analysis to Accelerate Development of New Vaccines and Monoclonal Antibodies

Manufacturing of consistently high quality products is the commitment of pharmaceutical industry. To achieve this, new products must be thoroughly tested and the results meet government-approved product specifications. Improving existing and adopting improved analytical technologies for product testing ensure the production of safe and effective products. This is particularly critical for the manufacturing of biologic products which, relative to small molecular drugs, have a larger size, are more complex in structure and are thus more difficult to characterize.

Application of Process Analytical Technologies for Diagnosis and Monitoring of Vaccine Antigens

The objective of the study is to exploit process analytical technologies within the framework of metabolic engineering to elucidate the causes of spectrofluorometric patterns relevant to biological formation of vaccine antigens. The ultimate benefit would be less variability in the processes which would minimize potential vaccine shortages.

Evaluate the impact on transmission dynamics and cost-effectiveness of pertussis booster vaccine for Canadian adolescents and adults

Pertussis or whooping cough is caused by the strict human pathogen B. pertussis or Bordetella parapertussis and is a highly contagious, potentially life-threatening respiratory tract illness when it occurs in unprotected infants. Despite the introduction of acellular pertussis (aP) vaccines and great initial success of the immunization program, pertussis outbreaks were reported in adolescents and adults in Canada since 1993. This trend was demonstrated as shift in pertussis epidemiology from infants and young children.

Pages